Breast Cancer Long-term Outcome of Cardiac Dysfunction

Breast Neoplasms Clinical Trial

— BLOC  

Official title:

Study of the Cardiovascular and Psychosocial Effects of the Treatment of Breast Cancer With Chemotherapy and/or Radiotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01904331
• Other study ID #: 686317
• Status: Completed
• Start date: June 2013
• Est. completion date: October 24, 2017

Study information

• Verified date: June 2018
• Source: University Medical Center Groningen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The purpose of this study is to assess the prevalence of cardiac dysfunction and (undiagnosed) heart failure in women registered in general practice with a history of breast cancer who received chemotherapy and / or radiotherapy as compared to a matched female control population.

Description:

Background:

Due to screening and progress in treatment the overall survival of women treated for breast cancer has increased over the last decades. Therefore, the long-term effects of breast cancer have emerged as an important topic. An increased mortality is seen within years post treatment due to an increased incidence of cardiac dysfunction among survivors of breast cancer. This increased mortality is related to long term side effects of treatment with chemotherapy and radiotherapy. Earlier studies into this topic have focused on specific patient groups and therefore these results are difficult to translate to the general population. Furthermore, most echo graphic studies have focused on the systolic dysfunction of the heart, which is a late stage of the cardiac deterioration. Detecting cardiotoxicity early on provides the opportunity for early treatment and might therewith prevent deterioration of cardiac function and improve the prognosis of patients

Objectives:

Primary objective

1. To assess the risk of a systolic and / or diastolic cardiac dysfunction at echocardiography of breast cancer patients compared to matched controls.

Secondary objective:

2. To assess the risk of heart failure( a combination of clinical complaints, objective measures at physical examination, laboratory examination or echocardiography) in breast cancer patients as compared to matched controls

3. To determine the value of patient characteristics, clinical complaints and signs in physical examination in diagnosing cardiac dysfunction as found of echocardiography

4. To determine the additional diagnostic value of biomarkers; N-terminal pro-hormone of brain natriuretic peptide (NT-pro-BNP) and high sensitive troponin T (hs-troponinT) in diagnosing cardiac dysfunction, as found on echocardiography

5. Genetic analysis

Study design and population:

This is a cross-sectional, observational study in women in general practice who have been curatively treated for breast cancer with chemo and / or radiotherapy at a minimum of 5 years ago and an age and general practitioner (GP) matched female control population. Patients must be 18 years or older, younger than 80 at the time of diagnosis, not been treated for other types of cancer with chemo- and/or radiotherapy and must be willing to give written informed consent Primary study parameters

1. Systolic and diastolic cardiac function of echocardiography

2. Hospital Anxiety and Depression Scale (HADS)

3. Multi dimensional Fatigue Inventory (MFI-20)

4. Cardiovascular Risk Management (CVRM)

5. Short physical examination: blood pressure, height, weight, waist circumference, electrocardiography, signs of edema, auscultation

6. Laboratory testing: Hemoglobin, hematocrit, leucocytes, creatinine , estimated glomerular filtration rate (GFR), cholesterol, triglycerides, High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Cholesterol/HDL ratio, C-reactive protein (CRP),Thyroid stimulating hormone (TSH), glucose

7. Serum and plasma for biomarkers

8. ethylenediaminetetraacetic acid (EDTA) -tube for DeoxyriboNucleic Acid (DNA) analysis Outcomes

Primary outcome:

The cardiac dysfunction will be related to type of therapy and compared to the age-and general practice matched control group. Information on type of therapy will be gathered trough contacting the hospitals were patients were treated.

Secondary outcome:

Symptoms and signs of women with cardiac dysfunction will be compared with those without cardiac dysfunction. A comparison between women treated for breast cancer and women without breast cancer will be made.

The level of the biomarkers will be linked with the cardiac dysfunction. In women treated for breast cancer with chemo- and/or radiotherapy these will also be linked with type of therapy.

DNA analysis will be carried out to investigate if changes in candidate genes are related to the development of cardiac dysfunction.

Burden and risks associated with participation, benefit and group relatedness The minimal invasive tests will be performed if patient are willing to participate in de study after contact trough letters. As far as known no serious adverse events are linked to the described study procedures.

With this study we hope to get insight in the risk of cardiac dysfunction after chemo- and/or radiotherapy in women treated for breast cancer. And to determine possibly diagnostic measure to detect this deterioration. Eventually, this may contribute to the early detection of cardiac dysfunction in women treated with chemo- and/or radiotherapy for breast cancer to improve the prognosis for patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 700
• Est. completion date: October 24, 2017
• Est. primary completion date: February 6, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• For breast cancer patients: minimum of 5 years after treatment for breast cancer with chemo- and/or radiotherapy and after 1970

• For breast cancer patients: younger than 80 at the time of diagnosis of breast cancer

• willing to sign an informed consent

• older than 18 at the time of inclusion

Exclusion Criteria:

• Treatment with chemo- and/or radiotherapy for other types of cancer besides breast cancer

• women who are unable to participate (e.g. terminally or mentally ill)

Related Conditions & MeSH terms

• Breast Neoplasms

Locations

Country	Name	City	State
Netherlands	University Medical Center Groningen (UMCG)	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Clinical complaints and signs at inclusion	Questionnaires (CVRM, HADS and MFI-20), a short physical examination and a electrocardiography at time of inclusion	on average 11 years after treatment with breast cancer
Primary	Cardiac dysfunction	systolic and diastolic parameters at time of inclusion	on average 11 years after treatment with breast cancer
Secondary	Biomarkers +DNA	Plasma EDTA, lithium-heparin plasma and serum are stored at -80 freezer at the the time of inclusion. Determination of biomarkers will take place at the end of the study period Whole blood is frozen for DNA analysis at time of inclusion.	on average 11 years after treatment with breast cancer